2000 - present

2000 - ZLB Bioplasma Established

In June 2000 CSL signed an agreement to acquire the plasma fractionation assets and business (ZLB) from Rotkreuzstiftung Zentrallaboratorium Blutspendedientst SRK, a non-profit organisation affiliated with the Swiss
Red Cross and with strong links to the international family of Red Cross organisations. ZLB is the fifth largest manufacturer of plasma products worldwide.

CSL Bioplasma launches new chromatography based plasma product portfolio.

2001 - ZLB Plasma Services Established

ZLB Plasma Services commenced operations in September 2001 following CSL's acquisition of 47 US-based plasma collection centres and associated laboratory facilities from Nabi. This acquisition secures plasma supply for the continued expansion of ZLB Bioplasma.

2002 - Expansion of Parkville Influenza Plant

CSL expands operations, effectively doubling the production of influenza vaccine to supply the demands in the Northern and Southern hemispheres.

CSL introduces Menjugate to the Australian market. Menjugate is a conjugated meningococcal C vaccine licensed from Chiron Corporation.

Opening of first regional office in Hong Kong.

2003 - CSL's thiomersal-free Influenza Vaccine Launched

Launch of CSL's thiomersal-free Fluvax influenza vaccine.

CSL Bioplasma's new purpose-built nucleic acid testing (NAT) laboratory commissioned.

CSL obtains US Human Papillomavirus Patent.

2004 - CSL Goes Global

CSL completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring, now known as CSL Behring, a global leader in plasma therapeutics.

Sale of Animal Health business to Pfizer Inc resulted in net proceeds of $161.6 million.

2005 - GARDASIL® – A Vaccine Against Cervical Cancer

CSL’s collaboration with Merck & Co. Inc and the University of Queensland to develop a cervical cancer vaccine succeeds. The product enters Phase III clinical trials and in 2006 receives FDA approval.

2006 - Vivaglobin® approved in U.K. and U.S.

Vivaglobin® is licensed for use in the U.K. and U.S. for adults and children who require antibody replacement due to primary immunodeficiency.